p53 transgenic mice are highly susceptible to 4-nitroquinoline-1-oxide- induced oral cancer

Molecular Cancer Research

Volumn 4, Issue 6, 2006, Pages 401-410

  Zhang, Zhongqiu ^a   Wang, Yian ^a   Yao, Ruisheng ^a   Lubet, Ronald A ^b   You, Ming ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; CARCINOGEN; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOASSAY; CANCER INCIDENCE; CANCER LOCALIZATION; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; ESOPHAGUS; GENE EXPRESSION PROFILING; GENE MUTATION; MICROARRAY ANALYSIS; MOUSE; MOUTH CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE; TUMOR GROWTH; UNINDEXED SEQUENCE; WILD TYPE;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; APOPTOSIS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; DISEASE MODELS, ANIMAL; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; MICE; MICE, TRANSGENIC; MOUTH NEOPLASMS; MUTATION, MISSENSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TONGUE NEOPLASMS;

MUS MUSCULUS;

EID: 33745823859     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0028     Document Type: Article

References (31)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. Jovanovic A, Schulten EA, Kostense PJ, Snow GB, van der Waal I. Tobacco and alcohol related to the anatomical site of oral squamous cell carcinoma. J Oral Pathol Med 1993;22:459-62.
3. Sugerman PB, Joseph BK, Savage NW. Review article: The role of oncogenes, tumour suppressor genes and growth factors in oral squamous cell carcinoma: a case of apoptosis versus proliferation. Oral Dis 1995;1:172-88.
4. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56: 2488-92.
5. Field JK. Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 1992;28B:67-76.
6. Greenblatt MS, Bennett WP, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
7. Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect 1996;104 Suppl 3:435-9.
8. Li FP, Fraumeni JF, Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-52.
9. Zhang Z, Liu Q, Lantry LE, et al. A germline p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents Taxol or Adriamycin. Cancer Res 2000;60:901-7.
10. Zhang Z, Li J, Lantry LE, et al. M, p53 transgenic mice are highly susceptible to 1,2-dimethylhydrazine-induced uterine sarcomas. Cancer Res 2002;62:3024-9.
11. Wang Y, Zhang Z, Kastens E, Lubet RA, You M. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice. Cancer Res 2003;63:4389-95.
12. Zhang Z, Wang Y, Lantry LE, et al. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene 2003;22:6257-65.
13. Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995;10:1217-27.
14. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-7.
15. Erber R, Conradt C, Homann N, et al. Bosch FX, TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998;16:1671-9.
16. Liloglou T, Scholes AG, Spandidos DA, Vaughan ED, Jones AS, Field JK. p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. Cancer Res 1997;57:4070-4.
17. Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
18. Zhang Y, Xiong Y Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 1999;3:579-91.
19. Hawkins BL, Heniford BW, Ackermann DM, Leonberger M, Martinez SA, Hendler FJ. 4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcinoma. Head Neck 1994;16:424-32.
20. Steidler NE, Reade PC. Experimental induction of oral squamous cell carcinomas in mice with 4-nitroquinoline-1-oxide. Oral Surg Oral Med Oral Pathol 1984;57:524-31.
21. Yuan B, Heniford BW, Ackermann DM, Hawkins BL, Hendler FJ. Harvey ras (H-ras) point mutations are induced by 4-nitroquinoline-1-oxide in murine oral squamous epithelia, while squamous cell carcinomas and loss of heterozygosity occur without additional exposure. Cancer Res 1996;54:5310-7.
22. Ohne M, Satoh T, Yamada S, Takai H. Experimental tongue carcinoma of rats induced by oral administration of 4-nitroquinoline 1-oxide (4NQO) in drinking water. Oral Surg Oral Med Oral Pathol 1985;59:600-7.
23. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266: 1821-8.
24. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992;356: 215-21.
25. Meyer JS, He W. High proliferative rates demonstrated by bromodeoxyuridine labeling index in breast carcinomas with p53 overexpression. J Surg Oncol 1994;56:146-52.
26. Gallo O, Sardi I, Pepe G, et al. Multiple primary tumors of the upper aerodigestive tract: is there a role for constitutional mutations in the p53 gene? Int J Cancer 1999;82:180-6.
27. Rowley H, Sherrington P, Helliwell TR, Kinsella A, Jones AS. p53 expression and p53 gene mutation in oral cancer and dysplasia. Otolaryngol Head Neck Surg 1998;118:115-23.
28. Qin GZ, Park JY, Chen SY, Lazarus P. A high prevalence of p53 mutations in pre-malignant oral erythroplakia. Int J Cancer 1999;80:345-8.
29. Ide F, Kitada M, Sakashita H, Kusama K, Tanaka K, Ishikawa T. p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene. Am J Pathol 2003;163: 1729-33.
30. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95:14863-8.
31. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet 2002;31:19-20.